Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

FDA-CDC Antimicrobial Resistance Isolate Bank: a Publicly Available Resource To Support Research, Development, and Regulatory Requirements.

Lutgring JD, Machado MJ, Benahmed FH, Conville P, Shawar RM, Patel J, Brown AC.

J Clin Microbiol. 2018 Jan 24;56(2). pii: e01415-17. doi: 10.1128/JCM.01415-17. Print 2018 Feb.

2.

Microbiological profile of a new topical antibacterial: retapamulin ointment 1%.

Scangarella-Oman NE, Shawar RM, Bouchillon S, Hoban D.

Expert Rev Anti Infect Ther. 2009 Apr;7(3):269-79. doi: 10.1586/eri.09.7. Review.

PMID:
19344241
3.

Molecular epidemiology of methicillin-resistant and methicillin-susceptible Staphylococcus aureus isolates from global clinical trials.

Goering RV, Shawar RM, Scangarella NE, O'Hara FP, Amrine-Madsen H, West JM, Dalessandro M, Becker JA, Walsh SL, Miller LA, van Horn SF, Thomas ES, Twynholm ME.

J Clin Microbiol. 2008 Sep;46(9):2842-7. doi: 10.1128/JCM.00521-08. Epub 2008 Jul 9.

4.

A geographic variant of the Staphylococcus aureus Panton-Valentine leukocidin toxin and the origin of community-associated methicillin-resistant S. aureus USA300.

O'Hara FP, Guex N, Word JM, Miller LA, Becker JA, Walsh SL, Scangarella NE, West JM, Shawar RM, Amrine-Madsen H.

J Infect Dis. 2008 Jan 15;197(2):187-94. doi: 10.1086/524684.

PMID:
18177252
5.

Topical retapamulin ointment (1%, wt/wt) twice daily for 5 days versus oral cephalexin twice daily for 10 days in the treatment of secondarily infected dermatitis: results of a randomized controlled trial.

Parish LC, Jorizzo JL, Breton JJ, Hirman JW, Scangarella NE, Shawar RM, White SM; SB275833/032 Study Team.

J Am Acad Dermatol. 2006 Dec;55(6):1003-13. Epub 2006 Oct 6.

PMID:
17097398
6.

A prodrug approach toward the development of water soluble fluoroquinolones and structure--activity relationships of quinoline-3-carboxylic acids.

Baker WR, Cai S, Dimitroff M, Fang L, Huh KK, Ryckman DR, Shang X, Shawar RM, Therrien JH.

J Med Chem. 2004 Sep 9;47(19):4693-709.

PMID:
15341485
7.

Antimicrobial effects of novel siderophores linked to beta-lactam antibiotics.

Kline T, Fromhold M, McKennon TE, Cai S, Treiberg J, Ihle N, Sherman D, Schwan W, Hickey MJ, Warrener P, Witte PR, Brody LL, Goltry L, Barker LM, Anderson SU, Tanaka SK, Shawar RM, Nguyen LY, Langhorne M, Bigelow A, Embuscado L, Naeemi E.

Bioorg Med Chem. 2000 Jan;8(1):73-93.

PMID:
10968267
8.

Aminoglycoside-resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled tobramycin treatment.

MacLeod DL, Nelson LE, Shawar RM, Lin BB, Lockwood LG, Dirk JE, Miller GH, Burns JL, Garber RL.

J Infect Dis. 2000 Mar;181(3):1180-4.

PMID:
10720551
9.

Characterization of a Pseudomonas aeruginosa efflux pump contributing to aminoglycoside impermeability.

Westbrock-Wadman S, Sherman DR, Hickey MJ, Coulter SN, Zhu YQ, Warrener P, Nguyen LY, Shawar RM, Folger KR, Stover CK.

Antimicrob Agents Chemother. 1999 Dec;43(12):2975-83.

10.

Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis.

Shawar RM, MacLeod DL, Garber RL, Burns JL, Stapp JR, Clausen CR, Tanaka SK.

Antimicrob Agents Chemother. 1999 Dec;43(12):2877-80.

11.

Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis.

Burns JL, Van Dalfsen JM, Shawar RM, Otto KL, Garber RL, Quan JM, Montgomery AB, Albers GM, Ramsey BW, Smith AL.

J Infect Dis. 1999 May;179(5):1190-6.

PMID:
10191222
12.

Rapid screening of natural products for antimycobacterial activity by using luciferase-expressing strains of Mycobacterium bovis BCG and Mycobacterium intracellulare.

Shawar RM, Humble DJ, Van Dalfsen JM, Stover CK, Hickey MJ, Steele S, Mitscher LA, Baker W.

Antimicrob Agents Chemother. 1997 Mar;41(3):570-4.

13.

Characterization of two unusual clinically significant Francisella strains.

Clarridge JE 3rd, Raich TJ, Sjösted A, Sandström G, Darouiche RO, Shawar RM, Georghiou PR, Osting C, Vo L.

J Clin Microbiol. 1996 Aug;34(8):1995-2000.

14.

Luciferase in vivo expression technology: use of recombinant mycobacterial reporter strains to evaluate antimycobacterial activity in mice.

Hickey MJ, Arain TM, Shawar RM, Humble DJ, Langhorne MH, Morgenroth JN, Stover CK.

Antimicrob Agents Chemother. 1996 Feb;40(2):400-7.

15.

Recovery of Coccidioides immitis from blood and abscess fluid using the BacT/alert system.

Shawar RM, Salyer JL, Ballou D, Clarridge JE.

Diagn Microbiol Infect Dis. 1995 Jan;21(1):15-9.

PMID:
7789092
16.

Diagnosis of intestinal tuberculosis by polymerase chain reaction on endoscopic biopsy specimens.

Anand BS, Schneider FE, El-Zaatari FA, Shawar RM, Clarridge JE, Graham DY.

Am J Gastroenterol. 1994 Dec;89(12):2248-9.

PMID:
7977255
17.

Large-scale use of polymerase chain reaction for detection of Mycobacterium tuberculosis in a routine mycobacteriology laboratory.

Clarridge JE 3rd, Shawar RM, Shinnick TM, Plikaytis BB.

J Clin Microbiol. 1993 Aug;31(8):2049-56.

18.
19.

Agrobacterium tumefaciens peritonitis mimicking tuberculosis.

Ramirez FC, Saeed ZA, Darouiche RO, Shawar RM, Yoffe B.

Clin Infect Dis. 1992 Dec;15(6):938-40.

PMID:
1457664
20.

Enhanced recovery of cytomegalovirus in conventional tube cultures with a spin-amplified adsorption.

Oefinger PE, Shawar RM, Loo SH, Tsai LT, Arnett JK.

J Clin Microbiol. 1990 May;28(5):965-9.

21.

Supplemental Content

Loading ...
Support Center